KIR2DL4 and breast carcinoma: Our prior research demonstrated that inhibiting the interaction of KIR2DL4 in NK cells can enhance the efficacy of trastuzumab treatment in breast cancer, suggesting that KIR2DL4 plays a crucial role as an immune checkpoint in NK cells [13, 14].